12/22
08:02 am
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $250.00 to $285.00. They now have a "buy" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $250.00 to $285.00. They now have a "buy" rating on the stock.
12/22
08:00 am
ntra
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/18
08:00 am
ntra
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
Low
Report
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
12/16
08:00 am
ntra
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
Low
Report
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
12/15
02:24 pm
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $250.00 to $260.00. They now have an "overweight" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $250.00 to $260.00. They now have an "overweight" rating on the stock.
12/15
08:04 am
ntra
Natera (NASDAQ:NTRA) was given a new $205.00 price target on by analysts at Wells Fargo & Company.
Low
Report
Natera (NASDAQ:NTRA) was given a new $205.00 price target on by analysts at Wells Fargo & Company.
12/15
07:02 am
ntra
Natera (NASDAQ:NTRA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
Natera (NASDAQ:NTRA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/12
08:00 am
ntra
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
Low
Report
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
12/10
08:52 pm
ntra
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer [Yahoo! Finance]
Low
Report
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer [Yahoo! Finance]
12/10
07:57 pm
ntra
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer
Low
Report
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer
12/9
08:00 am
ntra
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
Low
Report
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
12/8
01:20 pm
ntra
Natera (NASDAQ:NTRA) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $250.00 price target on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $250.00 price target on the stock.
12/8
08:07 am
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at BTIG Research from $230.00 to $260.00. They now have a "buy" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at BTIG Research from $230.00 to $260.00. They now have a "buy" rating on the stock.
12/5
07:00 am
ntra
Natera Acquires Foresight Diagnostics
Low
Report
Natera Acquires Foresight Diagnostics
12/3
08:00 am
ntra
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
Low
Report
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
12/2
08:00 am
ntra
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
Low
Report
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
12/1
06:03 pm
ntra
Natera (NASDAQ:NTRA) was given a new $265.00 price target on by analysts at Morgan Stanley.
Low
Report
Natera (NASDAQ:NTRA) was given a new $265.00 price target on by analysts at Morgan Stanley.
11/25
10:22 am
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $240.00 to $250.00. They now have an "overweight" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $240.00 to $250.00. They now have an "overweight" rating on the stock.
11/19
08:00 am
ntra
Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month
Low
Report
Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month
11/18
01:59 pm
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at UBS Group AG from $218.00 to $280.00. They now have a "buy" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at UBS Group AG from $218.00 to $280.00. They now have a "buy" rating on the stock.
11/14
08:22 am
ntra
Does Natera (NTRA) Have a Long Runway For Growth? [Yahoo! Finance]
Low
Report
Does Natera (NTRA) Have a Long Runway For Growth? [Yahoo! Finance]
11/13
09:36 am
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at Stephens from $197.00 to $235.00. They now have an "overweight" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at Stephens from $197.00 to $235.00. They now have an "overweight" rating on the stock.
11/12
08:00 am
ntra
Natera Integrates with Flatiron Health’s OncoEMR® Platform
Low
Report
Natera Integrates with Flatiron Health’s OncoEMR® Platform
11/11
12:21 pm
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at Morgan Stanley from $195.00 to $220.00. They now have an "overweight" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at Morgan Stanley from $195.00 to $220.00. They now have an "overweight" rating on the stock.
11/11
12:21 pm
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at Piper Sandler from $220.00 to $230.00. They now have an "overweight" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at Piper Sandler from $220.00 to $230.00. They now have an "overweight" rating on the stock.